Emerging Data and Future Directions in UC
Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.
ASCO GU 2022 Updates: PARP Inhibitors in First-Line and Subsequent UC Settings
Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.
ASCO GU 2022 Updates: Antibody-Drug Conjugates
Guru Sonpavde, MD, introduces emerging antibody-drug conjugates for treating metastatic UC, and reviews recent ASCO GU 2022 data on these regimens.
ASCO GU 2022 Updates: Trials on Combination Immunotherapy versus Chemotherapy
Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.
Remaining Unmet Needs in Frontline Maintenance Therapy and Ongoing Trials for mUC
The panel summarizes unmet needs in frontline maintenance therapy for UC and comments on ongoing trials for novel treatment regimens.
Treatment Options After Progression on Frontline Maintenance Therapy
Petros Grivas, MD, PhD, revisits the patient profile and invites panel members to share recommended treatment options for patients with or without FGFR mutations, who progress after chemotherapy and maintenance avelumab.
Maintenance Therapy Duration and Considerations for Treatment Interruption
Experts comment on the typical urothelial cancer maintenance therapy duration in their practice, and situations in which they might consider interrupting treatment while maintaining patient response.
Treatment for Cisplatin-Ineligible Patients with High PD-L1 Expression
Petros Grivas, MD, PhD, shares a clinical scenario of a cisplatin-ineligible patient with high PD-L1 expression and lymph node metastases, and experts weigh in on recommended treatment options.
Strategies and Barriers in mUC Maintenance Therapy
Panel members share insights into strategies and barriers to maintenance therapy for patients with bladder cancer.
Patient-Reported Outcome and Quality of Life Data on Maintenance Therapy
Thomas Powles, MBBS, MRCP, MD, comments on patient-reported outcome data and quality of life data in patients receiving maintenance therapy for metastatic urothelial cancer.
JAVELIN Bladder 101: Study Design and Patient Outcomes
Thomas Powles, MBBS, MRCP, MD, discusses recent data from the JAVELIN Bladder 100 trial on maintenance avelumab therapy plus best supportive care versus BSC alone.
The Role of Biomarkers in Immunotherapy Selection for mUC
Experts discuss the role of biomarkers in treatment selection for patients with metastatic UC.
Patient Profile: A 73-Year-Old Woman with Post-Cystectomy mUC
Petros Grivas, MD, PhD, introduces a patient profile of a woman with metastatic UC and invites panel members to comment on how they might approach initial treatment and management of the patient.
Recent Treatment Advances in Urothelial Cancer
Petros Grivas, MD, PhD, Shilpa Gupta, MD, Peter H. O’Donnell, MD, Thomas Powles, MBBS, MRCP, MD, and Guru Sonpavde, MD, summarize recent treatment advances for patients with urothelial cancer (UC).
Future Treatment Landscape of Metastatic Urothelial Carcinoma
Closing their discussion on metastatic urothelial carcinoma, panelists reflect on novel agents and the future treatment paradigm.
Selecting Second-Line Therapy for Metastatic Urothelial Carcinoma
Expert perspectives on the selection of second-line therapy after a patient has progressed on maintenance avelumab.
Metastatic Urothelial Carcinoma: Discussing Maintenance Therapy With Patients
Shared insight on how best to discuss maintenance therapy with patients being treated for metastatic urothelial carcinoma.
When to Use Maintenance Therapy in Metastatic Urothelial Carcinoma
Panelists consider whether the use of maintenance therapy is as prevalent after complete response or in patients with lesser PD-L1 expression.
Metastatic Urothelial Carcinoma: Experience With Maintenance Avelumab
Experts highlight the benefits of frontline avelumab maintenance therapy in patients with metastatic urothelial carcinoma.
Frontline Immunotherapy for Metastatic Urothelial Carcinoma
Experts discuss frontline immunotherapy for metastatic urothelial carcinoma when chemotherapy may not be an option.
Metastatic Urothelial Carcinoma: Optimizing Frontline Maintenance Therapy
Shared insight on best practices in frontline maintenance therapy for metastatic urothelial carcinoma to improve patient outcomes.
Selecting Frontline Therapy for Metastatic Urothelial Carcinoma
Reviewing a patient case of metastatic urothelial carcinoma, experts discuss the selection of frontline and maintenance therapy.
2 Commerce Drive Cranbury, NJ 08512